DMF Updates & Regulatory Filings

Longshine Boi-Tech's active regulatory dossiers across the United States, European Union, Latin America, Japan, Korea, the Middle East and Africa. Filings are organised by jurisdiction; Letter of Authorization (LoA) is issued to qualified buyers at no charge for ANDA, IND, NDA, EU Marketing Authorisation, UK MHRA, ANVISA, PMDA and other regulatory submissions.

60+
Active US FDA DMFs
12+
EDQM CEPs
560+
Catalogue SKUs
50+
Export markets

Filings by jurisdiction

Region Filing type Coverage Status
United StatesFDA Type II Drug Master File (DMF)60+ molecules — cardiovascular, anti-infective, oncology, CNS, endocrine, metabolicActive
European UnionEDQM Certificate of Suitability (CEP)Workhorse molecules — multiple Ph. Eur. monograph submissionsActive
European UnionActive Substance Master File (ASMF)Non-CEP molecules — Restricted & Applicant's Part dossiersActive
United KingdomUKMA + Windsor Framework ASMFUK-specific recognition for EU-CEP-listed moleculesActive
BrazilANVISA RDC 359/2020 dossierPortuguese-language CMC packages for Brazilian sponsorsActive
CanadaHealth Canada DMFCross-referenced from US FDA DMFsActive
MexicoCOFEPRIS sanitary registration supportReference letters for Mexican filingsActive
JapanPMDA Master File (J-DMF)Selected molecules — JP-grade release
South KoreaMFDS Drug Master FileSelected molecules — KP-grade release
RussiaRoszdravnadzorPer-molecule on buyer requestOn request
ChinaNMPAPer-molecule on buyer requestOn request
Saudi Arabia, UAEGCC SFDA dossier supportReference letters and CMC packagesActive
South AfricaSAHPRA dossierEnglish-language CMC packages

2026 filing activity

2026 · Q2
US FDA DMF refresh — cardiovascular & anti-infective portfolio
Annual update submissions for cardiovascular and anti-infective DMFs. Buyers with active ANDA references receive updated Letter of Authorization automatically.
2026 · Q2
EDQM CEP renewals — five workhorse molecules
5-yearly CEP renewals filed with EDQM for the cardiovascular and CNS molecules in our European catalogue. Renewal cycle includes EDQM site inspection.
2026 · Q1
Brazil ANVISA — three new dossiers
Three new ANVISA RDC 359/2020 dossiers submitted for Brazilian buyers in metabolic, oncology and CNS therapeutic areas. Portuguese-language CMC packages included.
2026 · Q1
WHO-GMP certificate renewal
Annual WHO-GMP renewal completed. Certificate valid through Q4 2028. Full audit report and inspector observations available to qualified buyers on request.
2025 · Q4
US FDA pre-approval inspection
FDA PAI conducted at the Pune facility. Closed without Form-483 observations. Inspection report available to ANDA sponsors on request.
2025 · Q4
Japan PMDA — first J-DMF submission
First J-DMF submitted to PMDA for a cardiovascular molecule. JP-grade release supported on every batch.

How to request a Letter of Authorization (LoA)

Once a supply agreement is in place with Longshine Boi-Tech, the Letter of Authorization is issued within 24 business hours by our QA Head, on company letterhead, with the active DMF / CEP / ASMF reference number, the molecule, the buyer's sponsor company and filing number, and the gateway address for direct regulatory submission. We support electronic gateway submission to FDA's ESG, EDQM's CESP, ANVISA's Solicita, and PMDA's electronic gateway.

Audit-ready documentation packages

Qualified buyers request the full Certificate of Analysis (CoA), Certificate of Origin (CoO), Certificate of GMP, ISO 9001:2015 certificate, FDA DMF Letter of Authorization, EDQM CEP, and Material Safety Data Sheet (SDS) as a single PDF bundle. Same-day turnaround once the mutual NDA is signed. Email regulatory@longshineboitech.com or open a request via the contact form.

Request LoA / DMF reference View certifications portfolio Quality system overview FDA DMF buyer guide